PUBLICATIONS

Full manuscripts are available at my ResearchGate page

Orchid page

 

Patents

  1. Bartfeld E and Lass A. Apparatus and method for obtaining an identification of drugs for enhanced safety. Patent Number 9031853. Issued May 12, 2015
  2. Bartfeld E and Lass A. System and Method for real time management of a drug regimen. Patent number: 7747454 issued June 29, 2010

Published Manuscripts

  1. Kaplan S, Bertoia ML, Lass A, Wang FT, Evans A, Dhanda S, Roy D, Seeger JD (2022). Delayed pregnancy detection and return to fertility with extended levonorgestrel-containing oral contraceptives: A real world setting cohort study. Pharmacoepidemiol Drug Saf. 2022 Jun 17. doi: 10.1002/pds.5497. Epub ahead of print. PMID: 35713281.
  2. Kaplan S, Bertoia ML, Wang FT, Zhou L, Lass A, Evans A, Dhanda S, Roy D, Seeger JD. (2022) Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States. 2022 Jan;105:26-32. doi: 10.1016/j.contraception.2021.09.013. Epub 2021 Sep 30. PMID: 34599911.Lass A & Lass G. (2021). Inequalities in assisted reproduction technology utilisation between the G20 countries. Hum Fertil (Camb). 2021 Dec 17:1-6. doi: 10.1080/14647273.2021.2017025. Epub ahead of print. PMID: 34915790.
  3. Lass A & Lass G. (2021) Is there a correlation between total fertility rate, utilization of assisted reproduction technology, and national wealth in Europe? J Med Econ. 2021 Jan-Dec;24(1):536-539. doi: 10.1080/13696998.2021.1917863. PMID: 33879012.
  4. Lass A,  Lass G, P–731 Correlation between fertility rate, utilisation of ART and gross domestic product across Europe, Human Reproduction, Volume 36, Issue Supplement_1, July 2021, deab130.730, https://doi.org/10.1093/humrep/deab130.730
  5. Kaplan S, Levy-Toledano R, Davies M, Roy D, Howles CM, Lass A. (2021) Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study. Front Endocrinol (Lausanne). 2021 Mar 16;12:632674. doi: 10.3389/fendo.2021.632674. PMID: 33815290; PMCID: PMC801035
  6. Kaplan S, Toussi M, Evans A, Dhanda S, Roy D, Lass A. (2021) Real world utilization of 91-day extended levonorgestrel-containing combined oral contraceptives in Europe: a multinational database study. Curr Med Res Opin. 2021 Mar;37(3):515-522.
  7. Lass A. (2020) Fertility and Pregnancy in patients with familial adenomatous polyposis (FAP). European Gynecology and Obstetrics. 2(2):73-76
  8. LassA, Chaudary W, Lass G. (2019) Correlation between gross domestic product, utilization of in vitro fertilization, and pregnancy success rate across the world. J Med Econ. Apr 23:1-5
  9. Lass A. & Montgomery M (2019): RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. J Med Econ. 2019 Jan 29:1-2
  10. Lass A, Belluzzi A. (2018) Omega 3 polyunsaturated fatty acids (PUFA) and in vitro fertilization (IVF) treatment. Reprod Biomed Online. Jan;38(1):95-99
  11. Newson LR, Lass A. Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms. Br J Gen Pract. 2018 Oct;68(675):499-500.
  12. Lass A and Newson RL. Omega 3 polyunsaturated fatty acids and the menopause. (2018) Post Reproductive Health 24 (3) 130-1.
  13. Andersen V, Banerji V, Hall G, Lass A, Emmanuel AV. (2018) The patient burden of opioid-induced constipation: new insights from a large, multinational survey in 5 European countries. United European Gastroenterol J. Oct;6(8):1254-1266
  14. Child T, Leonard S, Evans J, Lass A. (2018) Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology. Reprod Biomed Online 36(6):630-645.
  15. Lass A. (2018) Is single ovary a detrimental factor for live-birth rate in IVF? Hum Reprod. Feb 1. doi: 10.1093/humrep/dey007
  16. Lass A. (2017) Pharmaceutical industry contribution to research is essential but full transparency and guidelines are required, ,Hum Reprod. 32(10):2147-2148
  17. Lass A. (2015) Improving theReporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement- what about registration studies? Hum Reprod. 30(2):490
  18. Hovatta O, McVeigh E, Lass A, Homburg R (2009). A large Northern European observational study of follitropin alfa filled-by-mass pre-filled pen. RBMOnline Vol 18. No 4. 502-508
  19. Durnerin CI, Erb K, Fleming R, Hillier H, Hillier SG, Howles CM, Hugues JN, Lass A, Lyall H, Rasmussen P, Thong J, Traynor I, Westergaard L, Yates R Luveris Pretreatment Group. (2008)   Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod;23(2):421-6
  20. Lass A and McVeigh E. (2004) The routine use of r-hFSH Follitropin- alfa (GONAL-f) filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK. Biomed. Online. 9: 604-610.
  21. Lass A. (2004) Assessment of ovarian reserve – is there a role for ovarian biopsy? Debate continued. Hum. Reprod. 19; 467-9
  22. Lass A. (2004)  Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome. Hum. Reprod. 19: 217-218.
  23. Lass A. Vassiliev MA. Decosterd G. Warne D. Loumaye E.  (2002) The relationship of baseline ovarian volume to ovarian response in ovulation induction treatment in WHO II anovulatory patients using chronic low dose gonadotropin stimulation. Fertil Steril 78: 265-269.
  24. Lass A. Weiser W. Munafo A. Loumaye E. (2001) The role of Leukemia inhibitory factor (LIF) in human reproduction. Fertil Steril 76:1091-6
  25. Lass A, Akagbosu F. and Brinsden P. (2001) Sperm banking and ART treatment for couples following cancer treatment of the male partner. Hum. Reprod.Update. 7, 370-377.
  26. Lass (2001) Smoking and follicle numbers. Fertil Steril 75;1245-6.
  27. Lass A. (2001) Assessment of ovarian reserve – is there a role for ovarian biopsy? Hum. Reprod. 16;1055-1057.
  28. Lass A., and Brinsden P. (2001) How do patients choose a private IVF treatment?- a customer survey in a tertiary fertility center in the UK. Fertil. Steril. 75, 893-897.
  29. Abusheikha N, Lass A, Brinsden P. (2001) XX males without SRY gene and with infertility.  Hum Reprod. 16, 717-8.
  30. Abusheikha N., Lass A., Akagbosu F. and Brinsden P. (2001) In vitro fertilization cycles converted to intrauterine insemination because of poor follicular response have low success rate. Fertil. Steril. 75;634-635.
  31. Lass A. on behalf of the UK timing of hCG group (2003). Monitoring of IVF-ET cycles by ultrasound versus ultrasound and hormonal levels: a prospective, multicentre, randomized study. Fertil Steril 78: 265-269.
  32. Lass A., Gerrard A,  Abusheikha N, Akagbosu F. and Brinsden P. (2000) IVF performance of women who have fluctuating early follicular FSH levels. Assist. Reprod. Genet. 17; 566-573.
  33. Lass , Burnley A. and Brinsden P. (2000) Sperm cryopreservation for cancer patients. Fertil. Steril., 72, 418.
  34. Lass A, (1999) The fertility potential of women with a single ovary. Reprod. Update., 5, 546-550.
  35. Croucher C and Lass A, (1999) Predictive value of the results of a first IVF cycle. Hum Reprod., 14, 2417-2418.
  36. Lass A, Abusheika N. and Brinsden P. (1999) The effect of difficult embryo transfer on in vitro fertilisation (IVF) outcome. Reprod., 14, 2417.
  37. Lass A., Williams G., Abusheika N. and Brinsden P. (1999) The effect of endometrial polyps on outcomes of in vitro fertilization (IVF) cycles. Assist. Reprod. Genet., 16, 410-415.
  38. Lass A, (1999) What is the preferred treatment for hydrosalpinges? The ovary’s perspective. Reprod.,14, 1674-1677.
  39. Lass A, and Brinsden P. (1999) The role of ovarian volume in reproductive medicine. Reprod. Update, 5,256-266.
  40. Abusheikha N., Lass A., Akagbosu F. and Brinsden P. (1999) How useful is cervical dilatation in patients with cervical stenosis in an in vitro fertilization-embryo transfer programme? The Bourn Hall experience. Steril. 72, 610-612.
  41. Nahum R. Bzezinsky A., Lass A and Toth T. (1999) Age, Follicle-Stimulating Hormone, or Estradiol-Which is a better predictor of ovarian response in in vitro fertilization.  Assissted Reproduction 9, 176-179.
  42. Abusheikha N, Akagbosu F, Marcus S, Lass A, Cousins C, Brinsden P. (1999) Viral screening and assisted conception treatment- the Bourn Hall experience. J Assist Reprod Genet., 16, 337-339.
  43. Lass A, Abusheika N., Akagbosu F. and Brinsden P. (1999) Cancer patients should be offered semen cryopreservation BMJ 318, 1556.
  44. Lass A, Akagbosu F., Abusheikha N., Hassouneh M. Blayney M. Avery S. and Brinsden P. (1998) A program of semen cryopreservation for patients with malignant disease: Lessons from eight years experience. Hum Reprod, 11, 3256-3261.
  45. Lass A, Peat D., Avery S. and Brinsden P. (1998) Histological evaluation of  endometrium on the day of oocyte retrieval after GnRH-a/ FSH superovulation for IVF Hum Reprod, 11, 3203-3205.
  46. Abusheika N, Akagbosu F, Marcus S, Lass A, Cousins C and Brinsden P. (1998) Screening infertile couples for HIV infection. Steril., 70, 785.
  47. Lass A, Ellenbogen A, Croucher C, Trew G, Margara R, Becattini C and Winston RML (1998) The effect of salpingectomy on ovarian response to superovulation in an in-vitro fertilization embryo transfer programme. Fertil Steril, 70, 1035-1038.
  48. Lass A, Croucher C, Duffy S, Dawson K, Margara R and Winston R. (1998) 1000 initiated cycles of in vitro fertilization in women of 40 years old or more. Fertil Steril, 70, 1030-1034.
  49. Lass A, and Croucher C. (1998) Side of ovulationin in spontaneous cycles and during stimulation for In Vitro Fertilisation (IVF). Hum Reprod, 13, 244
  50. Croucher C, Lass A, Margara R and Winston R. (1998) Predictive value of the results of a first in vitro fertilization cycle on the outcome of subsequent cycles. Hum Reprod, 13, 403-408.
  51. Ben-Yair E, Lass A, Lev S, Ben-Yehoshua L, Tartakovsky B. (1997) Tumour necrosis factor alpha binding to human and mouse trophoblast. Cytokine 9, 830-836.
  52. Lass A, Croucher C, Margara R and Winston R. (1997) Right or left ovary, Which one is better? Hum Reprod, 12, 1730-1731.
  53. Lass A, Silye R, Abrams D.C, Krausz T, Margara R and Winston R.M.L (1997) Follicular density in ovarian biopsy of infertile woman: A novel method to assess ovarian reserve. Hum Reprod., 12, 1028-1031.
  54. Lass A, Paul M, Margara R and Winston RML. (1997) Women with one ovary have decreased response to GnRHa/HMG ovulation induction protocol in IVF programme but the same pregnancy rate as women with two ovaries. Hum Reprod., 12, 298-300
  55. Lass A, Skull J, McVeigh E, Margara R, Winston R. (1997) Measurement of ovarian volume by transvaginal sonography prior to Human Menopausal Gonadotrophin hyperstimulation can predict poor response of infertile patients in an IVF programme., Hum Reprod,., 12, 294-297.
  56. Ben-Yair E, Lass A, Lev S, Ben-Yehoshua L, Tartakovsky B (1997). Tumour necrosis factor alpha binding to human and mouse trophoblast. Cytokine. Nov;9(11):830-6.
  57. Lass A., Silye R, Abrams D.C, Krausz T, Margara R and Winston R.M.L (1996) Follicular density in ovarian biopsy of infertile woman: A novel method to assess ovarian reserve. J. Br. Fertil. Soc.
  58. Sinclair C.G, Lass A, Skull J, Delhanty J.D.A and Rodeck C. (1996) The role of chromosomal mosaicism in women with multiple miscarriage and IVF failure. J. Hum. Genet. 59: 2110.
  59. Hovatta O, Silye R, Kraus T, Abir R, Margara R, Trew G, Lass A, Winston R.M.L (1996) Cryopreservation of human ovarian tissue by using dimethyl-sulphoxide and propanediol-sucrose as cryoprotetants. Reprod.11:1268-1272.
  60. Ben Nun I, Lass A, Kaneti H, Ghetler Y, Shilon M, Shulman A, Bahary C, Beyth Y, Siegal A.(1992) Lack of correlation between hormonal blood levels and endometrial maturation in agonadal women with repeat implantation failure following embryo transfer from donated eggs: Assist Reprod Genet 9:102-105.
  61. Lass A, Goldberger S.; Bernheim B.; Ben nun I.; Fejgin M (1990) Vaginal prostaglandin E2 and Fatal amniotic fluid embolus. JAMA 263 (24):3259-3260.